N-(4-ethylphenyl)-3-(4-(2-methoxyphenyl)piperazine-1-carbonyl)-4-methylbenzenesulfonamide | 1245035-68-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: N-(4-ethylphenyl)-3-(4-(2-methoxyphenyl)piperazine-1-carbonyl)-4-methylbenzenesulfonamide
• 英文别名: N-(4-ethylphenyl)-3-[4-(2-methoxyphenyl)piperazine-1-carbonyl]-4-methylbenzenesulfonamide
• CAS: 1245035-68-0
• 化学式: C₂₇H₃₁N₃O₄S
• 分子量: 493.627
• InChiKey: GMZWKMZMDDSHKX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  35
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  87.3
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• [EN] THERAPEUTICALLY ACTIVE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER CHARACTERIZED AS HAVING AN IDH MUTATION<br/>[FR] COMPOSÉS THÉRAPEUTIQUEMENT ACTIFS DESTINÉS AU TRAITEMENT D'UN CANCER CARACTÉRISÉ PAR UNE MUTATION IDH
  申请人：AGIOS PHARMACEUTICALS INC

  公开号：WO2011072174A1

  公开（公告）日：2011-06-16

  Compounds and compositions comprising compounds useful in the treatment of cancer are described herein. The compounds and compositions can be used to modulate an isocitrate dehydrogenase (IDH) mutant (e.g., IDHIm or IDH2m) having alpha hydroxyl neoactivity.

  本文描述了用于治疗癌症的化合物和组合物。这些化合物和组合物可用于调节具有α-羟基新活性的异柠檬酸脱氢酶（IDH）突变体（例如IDH1m或IDH2m）。
• Methods and compositions for cell-proliferation-related disorders
  申请人：Agios Pharmaceuticals, Inc.

  公开号：US10610125B2

  公开（公告）日：2020-04-07

  Methods of treating and evaluating subjects having neoactive mutants are described herein.

  本文描述了治疗和评估具有新活性突变体的受试者的方法。
• METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS
  申请人：Dang Leonard Luan C

  公开号：US20150240286A1

  公开（公告）日：2015-08-27

  Methods of treating and evaluating subjects having neoactive mutants of IDH (e.g., IDH1 or IDH2).

  治疗和评估具有IDH新活性突变体（例如IDH1或IDH2）的受试者的方法。
• THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE
  申请人：Saunders Jeffrey O.

  公开号：US20130035329A1

  公开（公告）日：2013-02-07

  Compounds and compositions comprising compounds useful in the treatment of cancer are described herein.

  本文描述了在治疗癌症方面有用的化合物和组合物。
• Methods for diagnosing IDH-mutant cell proliferation disorders
  申请人：Agios Pharmaceuticals, Inc.

  公开号：US10711314B2

  公开（公告）日：2020-07-14

  Methods of diagnosing subjects having a cell proliferation-related disorder or suspected of having a cell proliferation-related disorder associated with mutant IDH enzymes with 2HG neoactivity.

  诊断患有细胞增殖相关疾病或疑似患有细胞增殖相关疾病的受试者与具有 2HG 新生活性的突变 IDH 酶有关的方法。